110 related articles for article (PubMed ID: 26899942)
1. Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database.
Wolff I; May M; Hoschke B; Zigeuner R; Cindolo L; Hutterer G; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Feciche B; Truss M; Dalpiaz O; Figenshau RS; Madison K; Sánchez-Chapado M; Santiago Martin MD; Salzano L; Lotrecchiano G; Shariat SF; Hohenfellner M; Waidelich R; Stief C; Miller K; Pahernik S; Brookman-May S;
Eur J Surg Oncol; 2016 May; 42(5):744-50. PubMed ID: 26899942
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma.
Kim SP; Crispen PL; Thompson RH; Weight CJ; Boorjian SA; Costello BA; Lohse CM; Leibovich BC
Cancer; 2012 Sep; 118(18):4412-20. PubMed ID: 22952032
[TBL] [Abstract][Full Text] [Related]
3. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
4. Contemporary external validation of the Leibovich model for prediction of progression after radical surgery for clear cell renal cell carcinoma.
Beisland C; Gudbrandsdottir G; Reisæter LA; Bostad L; Wentzel-Larsen T; Hjelle KM
Scand J Urol; 2015 Jun; 49(3):205-10. PubMed ID: 25423093
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial.
Aitchison M; Bray CA; Van Poppel H; Sylvester R; Graham J; Innes C; McMahon L; Vasey PA
Eur J Cancer; 2014 Jan; 50(1):70-7. PubMed ID: 24074763
[TBL] [Abstract][Full Text] [Related]
6. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
Oza B; Eisen T; Frangou E; Stewart GD; Bex A; Ritchie AWS; Kaplan R; Smith B; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Joniau S; Hancock B; Hermann GG; Bellmunt J; Parmar MKB; Royston P; Meade A
J Clin Oncol; 2022 Jun; 40(16):1772-1782. PubMed ID: 35213214
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer.
Haughey BH; Sinha P
Laryngoscope; 2012 Sep; 122 Suppl 2():S13-33. PubMed ID: 22926949
[TBL] [Abstract][Full Text] [Related]
8. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
Itano NB; Blute ML; Spotts B; Zincke H
J Urol; 2000 Aug; 164(2):322-5. PubMed ID: 10893575
[TBL] [Abstract][Full Text] [Related]
9. High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?
Fallara G; Bandini M; Larcher A; Pederzoli F; Karakiewicz P; Tian Z; Briganti A; Necchi A; Salonia A; Bertini R; Montorsi F; Bex A; Capitanio U
Curr Probl Cancer; 2021 Dec; 45(6):100759. PubMed ID: 34130863
[TBL] [Abstract][Full Text] [Related]
10. Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients.
Grasso M; Fishman AI; Cohen J; Alexander B
BJU Int; 2012 Dec; 110(11):1618-26. PubMed ID: 22458598
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma.
Tan MH; Kanesvaran R; Li H; Tan HL; Tan PH; Wong CF; Chia KS; Teh BT; Yuen J; Chong TW
Urology; 2010 Jun; 75(6):1365-1370; 1370.e1-3. PubMed ID: 20022084
[TBL] [Abstract][Full Text] [Related]
12. The key role of time in predicting progression-free survival in patients with renal cell carcinoma treated with partial or radical nephrectomy: conditional survival analysis.
Abdollah F; Suardi N; Capitanio U; Matloob R; Fossati N; Castiglione F; Di Trapani E; Di Trapani D; Russo A; Carenzi C; Montorsi F; Rigatti P; Bertini R
Urol Oncol; 2014 Jan; 32(1):43.e9-16. PubMed ID: 23911684
[TBL] [Abstract][Full Text] [Related]
13. Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease.
Blute ML; Amling CL; Bryant SC; Zincke H
Mayo Clin Proc; 2000 Oct; 75(10):1020-6. PubMed ID: 11040850
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
Doehn Ch; Richter A; Lehmacher W; Jocham D
Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
[TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence.
Eggener SE; Yossepowitch O; Pettus JA; Snyder ME; Motzer RJ; Russo P
J Clin Oncol; 2006 Jul; 24(19):3101-6. PubMed ID: 16809736
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.
Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Rajwa P; Yanagisawa T; Mostafaei H; König F; Aydh A; Pradere B; Enikeev D; Karakiewicz PI; Schmidinger M; Shariat SF
Eur Urol Oncol; 2022 Feb; 5(1):120-124. PubMed ID: 34992006
[TBL] [Abstract][Full Text] [Related]
17. 10-year oncologic outcomes after laparoscopic and open partial nephrectomy.
Lane BR; Campbell SC; Gill IS
J Urol; 2013 Jul; 190(1):44-9. PubMed ID: 23306087
[TBL] [Abstract][Full Text] [Related]
18. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
[TBL] [Abstract][Full Text] [Related]
19. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up.
Olweny EO; Park SK; Tan YK; Best SL; Trimmer C; Cadeddu JA
Eur Urol; 2012 Jun; 61(6):1156-61. PubMed ID: 22257424
[TBL] [Abstract][Full Text] [Related]
20. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
